Cervical Cancer: Causes, Symptoms, Screening, Stages, and Treatment (Complete Guide)

Cervical cancer is one of the most preventable cancers in modern medicine — yet it remains the third most common gynecologic malignancy worldwide. Every year, hundreds of thousands of women are diagnosed, and roughly half of them do not survive. Most of these deaths are not the result of an aggressive disease that cannot be treated. They are the result of a disease that was not caught in time.

What makes cervical cancer unique among cancers is how much is actually known about its cause, its progression, and its prevention. Nearly all cases are driven by a single virus. The path from infection to cancer takes years, sometimes decades. And during most of that path, the disease can be detected, treated, and stopped — often before it ever becomes cancer at all.

This guide explains how cervical cancer develops, who is at risk, how it is screened for and diagnosed, how it is staged, and what treatment options are available today — including options that preserve fertility in younger women.

What Is Cervical Cancer?

Cervical cancer is a malignancy that begins in the cells of the cervix — the lower part of the uterus that connects to the vagina.

Unlike many other cancers, cervical cancer usually develops slowly. It does not appear suddenly. It progresses through a long sequence of cellular changes, beginning with mild abnormalities in the surface cells of the cervix and advancing, over years, toward precancerous lesions and eventually invasive cancer.

This slow progression is what makes cervical cancer different. It gives medicine a window — often a very long one — to detect the disease before it becomes dangerous. That window is the reason routine gynecologic screening exists, and the reason it works.

The Two Main Types

Most cervical cancers fall into one of two categories:

Squamous cell carcinoma accounts for the majority of cases. It develops in the flat, thin cells lining the outer part of the cervix — the area most commonly examined during a Pap smear.

Adenocarcinoma develops in the glandular cells of the cervical canal. It is less common but has become increasingly prevalent in recent decades, and it can be harder to detect with standard screening because it arises deeper inside the cervix.

Both types share the same primary cause — and the same underlying prevention strategy.

The Primary Cause: HPV

The overwhelming majority of cervical cancers — more than 99% — are caused by persistent infection with the human papillomavirus (HPV).

HPV is one of the most common sexually transmitted infections in the world. Most sexually active adults will be exposed to it at some point in their lives. In the vast majority of cases, the immune system clears the virus on its own within one to two years, without causing any long-term harm.

The problem is persistence. When the infection does not clear — when the virus remains in the cervical cells for years — it can gradually alter how those cells divide, grow, and behave. Over time, this chronic cellular stress can lead to precancerous changes, and eventually to invasive cancer.

High-Risk HPV Strains

Not all strains of HPV carry the same risk. Of the more than 100 known strains, only a small group is strongly associated with cancer. The highest-risk types are HPV 16, 18, 31, 33, and 45. Types 16 and 18 alone are responsible for approximately 70% of all cervical cancer cases globally.

Identifying which strain a woman carries has become an important part of modern screening — and a key factor in determining how closely she needs to be monitored.

For a deeper explanation of how HPV causes cellular changes and which strains carry the highest risk, see HPV Virus: Types, Transmission, and Link to Cervical Cancer.

Prevention Through Vaccination

Because HPV is the primary driver of cervical cancer, vaccination against the virus is one of the most powerful prevention tools in modern oncology. The HPV vaccine protects against the strains most commonly linked to cervical, vaginal, vulvar, anal, and oropharyngeal cancers.

The vaccine is most effective when administered before exposure to the virus — which is why it is typically given to adolescents. It is included in the national immunization program in many countries, where it is offered free of charge through schools and is available for both boys and girls.

Despite its availability, uptake remains uneven. Public awareness and parental understanding remain critical factors in closing the gap.

For a full breakdown of who should get vaccinated and when, see HPV Vaccination: Who Should Get It and When.

Who Is at Risk?

While HPV is the central cause of cervical cancer, several additional factors can increase risk — either by making HPV infection more likely, or by making it harder for the body to clear the virus.

Age

Cervical cancer is unusual among cancers in that it affects women across a wide age range. It has two distinct peaks of incidence: one between the ages of 35 and 40, and another between 55 and 60. This is important — cervical cancer is not a disease of older age alone. Young women can and do develop it, and the emotional and reproductive implications in that group are particularly significant.

Sexual History

Risk is elevated in women who begin sexual activity at a young age, who have multiple partners, or whose partners have had multiple partners. This is not a moral observation — it is an epidemiological one. More exposure to potential HPV infection translates into a higher statistical risk.

It is important to emphasize that most sexually active women will not develop cervical cancer. The risk is cumulative and modifiable — which is exactly why screening matters.

Smoking

Women who smoke are roughly twice as likely to develop cervical cancer as non-smokers. The mechanism is well-understood: tobacco byproducts can be detected directly in cervical mucus, where they appear to damage the DNA of cervical cells and weaken the local immune response, making it harder for the body to clear HPV.

Immune Suppression

Any condition that weakens the immune system increases cervical cancer risk. This includes women living with HIV, those receiving immunosuppressive therapy after organ transplantation, and patients taking chronic corticosteroids or biologic medications. A weakened immune system is less capable of clearing HPV, allowing persistent infection to progress.

Long-Term Oral Contraceptive Use

Long-term use of combined oral contraceptives has been associated with a modest increase in cervical cancer risk, particularly in women who also carry high-risk HPV. The risk appears to decline after discontinuation.

Multiple Pregnancies

Women who have had several full-term pregnancies show a slightly elevated risk, likely due to hormonal and immunological changes during pregnancy.

Why Screening Matters So Much

Cervical cancer is unusual in that it is preceded, almost always, by a long precancerous phase. This phase does not cause symptoms. A woman may feel completely healthy while cellular changes are already taking place in her cervix.

This is the critical point: waiting for symptoms is not a viable prevention strategy. By the time cervical cancer produces noticeable symptoms, it is often already invasive. This is why routine gynecologic screening — regardless of how a woman feels — is one of the most important pillars of prevention.

The Pap Smear

The Pap smear, developed in the mid-twentieth century, remains a cornerstone of cervical cancer screening. It involves collecting a small sample of cells from the surface of the cervix, which are then examined under a microscope for abnormalities.

What the Pap smear detects is not cancer itself — it is cellular change. It identifies cells that look different from healthy cervical cells, long before those changes have progressed to cancer. This is precisely what makes it effective.

HPV Testing

Modern screening has expanded beyond the Pap smear alone. HPV DNA testing can identify the presence of high-risk viral strains directly, often before any cellular changes are visible. In many countries, co-testing — combining the Pap smear with an HPV test — has become the standard of care for women over 30.

For a full comparison of screening methods and when each is appropriate, see Pap Smear vs HPV Test: Understanding Cervical Cancer Screening.

Precancerous Lesions

When screening detects abnormal cells, they are classified by severity into what is called cervical intraepithelial neoplasia, or CIN. CIN 1 represents mild changes, CIN 2 represents moderate changes, and CIN 3 represents severe changes — the stage immediately preceding invasive cancer.

Mild lesions often regress on their own as the immune system clears the underlying HPV infection. Moderate and severe lesions, however, require treatment to prevent progression. These treatments — typically performed in an outpatient setting — include laser ablation, cryotherapy (freezing), or a small surgical excision known as conization.

For a full explanation of the CIN grading system and how each stage is managed, see Precancerous Lesions of the Cervix: CIN 1, 2, and 3 Explained.

Symptoms of Cervical Cancer

In its earliest stages — particularly the precancerous stage — cervical cancer produces no symptoms at all. This is the defining challenge of the disease.

Symptoms typically appear only when the cancer has become invasive. By then, treatment is still possible, but the clinical situation is more complex.

The Most Common Symptoms

The symptoms most strongly associated with cervical cancer include:

• Irregular vaginal bleeding between periods
• Bleeding after sexual intercourse — often the earliest symptom
• Unusual vaginal discharge, sometimes with odor
• Pelvic pain, particularly during intercourse
• Pain or bleeding after menopause

None of these symptoms is specific to cervical cancer. Many are caused by benign conditions. But any persistent or unexplained change — particularly bleeding that does not fit a woman's normal cycle — warrants gynecologic evaluation.

For a more detailed look at early symptoms and when to act on them, see Early Symptoms of Cervical Cancer You Should Not Ignore.

The Importance of Not Dismissing Symptoms

Many women delay evaluation because the symptoms feel mild, embarrassing, or easy to explain away. Bleeding after intercourse can be attributed to minor irritation. Unusual discharge can be blamed on infection. Pelvic pain can be dismissed as normal.

These explanations are often correct. But they are not always correct. Cervical cancer rarely announces itself clearly — and the women who catch it early are almost always the ones who investigate symptoms that others might have ignored.

Diagnosis

When cervical cancer is suspected — either because of an abnormal screening result or because of symptoms — a structured diagnostic process follows.

Colposcopy and Biopsy

The first step is usually a colposcopy: a close visual examination of the cervix using a specialized magnifying instrument. If suspicious areas are identified, a small tissue sample — a biopsy — is taken for pathological analysis.

Pathology is what confirms or rules out cancer. It also identifies the specific cell type, which influences treatment planning.

Imaging Studies

Once a diagnosis of invasive cervical cancer is confirmed, imaging is used to determine the extent of disease. Two studies are typically performed:

MRI of the pelvis provides detailed visualization of the cervix, uterus, and surrounding pelvic structures. It is the best imaging tool for assessing local tumor extension.

PET-CT evaluates the entire body for signs of spread, including to pelvic lymph nodes, distant lymph nodes, and organs outside the pelvis.

Together, these studies answer the central clinical questions: Is the cancer limited to the cervix? Has it invaded nearby tissues? Has it reached the lymph nodes? Are there distant metastases?

The answers determine the stage of the disease — and the stage determines treatment.

Staging: Understanding the Extent of Disease

Cervical cancer is staged using the FIGO system (International Federation of Gynecology and Obstetrics), which classifies disease into four broad stages based on how far it has spread.

Stage 1 describes cancer confined to the cervix. Within this stage, substages distinguish microscopic disease from larger tumors still limited to the cervix.

Stage 2 describes cancer that has spread beyond the cervix — to the upper vagina or the tissues surrounding the uterus — but not to the pelvic wall or the lower third of the vagina.

Stage 3 describes cancer that has reached the pelvic wall, the lower vagina, or nearby lymph nodes, or that has caused kidney obstruction.

Stage 4 describes cancer that has spread to the bladder, rectum, or distant organs.

Staging is not just academic. It is the single most important factor in determining prognosis and selecting the right treatment. A woman with Stage 1 disease may be a candidate for surgery alone, potentially preserving fertility. A woman with Stage 3 disease will typically require combined radiation and chemotherapy. The distinction is profound.

For a full explanation of how FIGO staging is determined and how it guides treatment decisions, see Cervical Cancer Staging: How FIGO Classification Guides Treatment.

Treatment

Treatment for cervical cancer is highly individualized, shaped by the stage of disease, the patient's age, her reproductive wishes, and her overall health.

Surgery

For early-stage disease, surgery is often the primary treatment. The standard procedure is a radical hysterectomy, which removes the uterus, cervix, upper vagina, and surrounding tissues, typically along with the pelvic lymph nodes.

Radical hysterectomy is an effective treatment but it is also a significant procedure — one that ends reproductive potential and carries its own recovery process. This is why, in carefully selected cases, a different surgical approach is increasingly offered.

Fertility-Sparing Surgery

For younger women diagnosed at an early stage who wish to preserve the ability to conceive, fertility-sparing surgery has become an established option. The most common form is a procedure called radical trachelectomy, which removes the cervix and the upper part of the vagina while leaving the uterus intact. After recovery, pregnancy remains possible — typically followed by a cesarean delivery.

Not every patient is a candidate. The tumor must be small, limited to the cervix, and of a cell type that responds well to this approach. Careful preoperative imaging and pathology are essential. But for the right patient, fertility-sparing surgery offers something that radical hysterectomy cannot — the possibility of treating the cancer without closing the door on future motherhood.

For a full explanation of eligibility, procedure, and outcomes, see Fertility-Sparing Surgery for Cervical Cancer: What to Know.

Radiation Therapy

Radiation is used for locally advanced disease, either as the primary treatment or in combination with surgery and chemotherapy. Modern cervical cancer radiotherapy typically combines external beam radiation with internal radiation (brachytherapy), delivered directly to the cervix.

Chemotherapy and Targeted Therapy

Chemotherapy is most often combined with radiation (chemoradiation) for Stage II and Stage III disease, where it significantly improves outcomes. For advanced or recurrent disease, targeted therapies and immunotherapy — including checkpoint inhibitors — have expanded the treatment landscape in recent years, offering new options for patients who previously had few.

For a complete overview of treatment pathways at each stage, see Treatment Options for Cervical Cancer: Surgery, Radiation, and Chemotherapy.

Cervical Cancer in Young Women

Although cervical cancer is often associated with middle age, it affects women in their twenties and thirties with meaningful frequency. The implications in this age group are significant — for fertility, for relationships, and for long-term quality of life.

Young women diagnosed with cervical cancer face decisions that older patients may not. Fertility preservation becomes a central consideration. Treatment choices weigh heavily against reproductive goals. Psychosocial support is often as important as medical care.

This is one of the reasons early detection matters so profoundly in this population. A young woman diagnosed at Stage I has options — including fertility-sparing surgery — that simply do not exist at later stages.

For more on this topic, see Cervical Cancer in Young Women: Why Early Detection Matters.

Life After Treatment

For women who complete treatment successfully, life after cervical cancer is shaped by two ongoing priorities: monitoring for recurrence, and managing the physical and emotional effects of treatment.

Follow-up typically includes regular gynecologic examinations, Pap testing, and imaging when indicated. The intensity of follow-up decreases over time, but surveillance never fully ends.

For women who underwent fertility-sparing surgery, pregnancy planning becomes a central conversation — one that involves close collaboration between gynecologic oncology and reproductive medicine.

For women who had hysterectomy or radiation, long-term effects may include hormonal changes, pelvic floor changes, and sexual health considerations — all of which deserve attention and can be managed effectively with the right care.

For a full overview of recovery and long-term follow-up, see Life After Cervical Cancer: Recovery, Follow-Up, and Fertility.

When to See a Specialist

Cervical cancer sits at the intersection of gynecology and oncology — and the complexity of treatment means that specialist care matters. A gynecologic oncologist is a surgeon trained specifically in the diagnosis and treatment of gynecologic cancers, and outcomes are consistently better when these cancers are managed by physicians with this training.

Specialist evaluation is particularly important for:

• Confirmed diagnosis of cervical cancer at any stage
• Precancerous lesions that recur or do not respond to initial treatment
• Complex or unusual pathology findings
• Women considering fertility-sparing treatment
• Patients seeking a second opinion on treatment planning

For guidance on when to seek specialist care, see When Should You See a Gynecologic Oncologist?.

Conclusion

Cervical cancer is, in many ways, a paradox. It is one of the most preventable cancers in medicine — and yet it continues to kill half of the women it diagnoses. The reason is not biology. It is timing.

The disease develops slowly, usually over years. It is caused by a virus that can be vaccinated against. It is preceded by precancerous changes that can be detected by a simple screening test. And in its early stages, it can often be treated with excellent outcomes — sometimes without removing the uterus at all.

Every one of these facts represents an opportunity. Vaccination prevents infection. Screening detects changes before they become cancer. Early diagnosis expands treatment options. Specialist care improves outcomes at every stage.

For women, the practical takeaway is straightforward: awareness, vaccination, and routine gynecologic care are not optional. They are the difference between a disease that is detected early and treated successfully, and one that is found too late.

Cervical cancer is beatable. The question is whether it is caught in time.

About the Author

Dr. Gadi Neuman

MD, MHA

View Profile

Clinical focus is urology and urological surgery with particular expertise in general urology, prostate conditions, urinary continence in men and women, urologic oncology, and male fertility. Patients are treated for prostate disorders, tumors of the urinary system including kidney, bladder, testicular, and prostate cancer, urinary tract dysfunction, urodynamic disorders, and erectile dysfunction.

Training in medicine was completed at the Sackler Faculty of Medicine, Tel Aviv University, followed by residency in Urology at Beilinson Hospital. A Master's degree in Health Systems Management was completed at Ben-Gurion University of the Negev, and further subspecialty training in urodynamics was completed in Bristol, England.

Current roles include Deputy Director of Rabin Medical Center, encompassing Beilinson and HaSharon Hospitals, and Director of the Urological Service at the "Mor" Institute. Surgical practice is conducted at Assuta Medical Center and Herzliya Medical Center. A faculty member of Ben-Gurion University of the Negev, with professional memberships including the Israeli Urological Association, the European Association of Urology, and the Israel Surgical Association.

Also serves as Deputy President of Lema'anchem, a leading medical support organization that helps patients navigate complex diagnoses and access world-class medical expertise.

Editorial Note

This article was reviewed and formatted by the MED.COM editorial process to align with international clinical standards.

Medical Disclaimer

This content is provided for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare professional regarding any medical condition.